An Open-Label, Multicenter Extension Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Bavituximab) in Patients with Refractory Advanced Solid Tumor Malignancies.

Trial Profile

An Open-Label, Multicenter Extension Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Bavituximab) in Patients with Refractory Advanced Solid Tumor Malignancies.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 15 Apr 2009

At a glance

  • Drugs Bavituximab (Primary)
  • Indications Advanced breast cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Peregrine Pharmaceuticals
  • Most Recent Events

    • 15 Apr 2009 Additional lead trial centre and sponsor (Peregrine Pharmaceuticals) added as reported by M.D. Anderson Cancer Center.
    • 23 Dec 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top